Comparison of the Neointima Inhibition Between Paclitaxel- and Sirolimus-Eluting Expanded Polytetrafluoroethylene Hemodialysis Grafts in a Porcine Model
| Autor: | Dae Joong Kim, Insu Baek, Jinsun Hwang, Heasun Kim, Jong-Sang Park, AJin Cho |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Neointima
Neointimal hyperplasia medicine.medical_specialty Intimal hyperplasia business.industry Urology General Chemistry Anastomosis Hyperplasia medicine.disease chemistry.chemical_compound surgical procedures operative Paclitaxel chemistry Sirolimus medicine.artery medicine Common carotid artery business medicine.drug |
| Zdroj: | Bulletin of the Korean Chemical Society. 34:1663-1667 |
| ISSN: | 0253-2964 |
| DOI: | 10.5012/bkcs.2013.34.6.1663 |
| Popis: | Neointimal hyperplasia causes vascular access dysfunction in hemodialysis patients with synthetic arteriovenous (AV) grafts. Several studies have reported that paclitaxel- or sirolimus-eluting AV grafts inhibit neointimal hyperplasia and display lower rates of stenosis compared with control grafts. However, there have been few comparative studies of the efficacy of paclitaxel- and sirolimus-eluting grafts. We compared the neointimal hyperplasia of paclitaxel- and sirolimus-eluting grafts. AV grafts were implanted laterally between the common carotid artery and the external jugular vein in 12 female Landrace pigs. The animals were sacrificed six weeks after surgery. The neointimal hyperplasia at the anastomosis sites of the grafts was quantified using the ratio of the intragraft hyperplasia to the graft area (H/G ratio) at the graft–vessel interface. The area of intimal hyperplasia at the venous (paclitaxel 1.06 [0.72-1.56] vs sirolimus 2.40 [1.72-3.0] mm 2 , P = 0.04) and arterial anastomosis sites (paclitaxel 0.93 [0.57-1.48] vs sirolimus 2.40 [1.72-3.0] mm 2 , P = 0.04) was significantly different between the two groups. However, the H/G ratios for the venous anastomosis site (paclitaxel 0.25 (0.17-0.38) vs sirolimus 0.38 (0.2-0.66), P = 0.4) and the arterial anastomosis site (paclitaxel 0.19 (0.08-0.39) vs sirolimus 0.41 (0.34-0.50), P = 0.1) did not differ significantly between the groups. In conclusion, there was no significant difference in the inhibition of neointimal hyperplasia by sirolimus- and paclitaxel-eluting AV grafts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|